Grant-funded, investigator-initiated trials fail to bounce back from COVID as 50% of research staff left for higher-paying jobs

George Sigounas named the first-ever chief science advisor at NCI

George Sigounas, an expert in bone marrow transplantation, was named to the newly created post of chief science advisor at NCI.

Success rates for RPGs at NCI would plummet from 13.4% to 8.3% if Trump’s FY2026 budget is enacted

Congressional Justifications displaying the details of the President Trump’s budget request for the fiscal year 2026 show that the success rates for Research Project Grants at NCI would plummet from 13.4% in FY2024 to 8.3% during the next fiscal year.

FDA booth stood empty at 2025 ASCO annual meeting

Booth 10025 became an unlikely crowd magnet at the exhibit hall at the annual meeting of the American Society of Clinical Oncology that ended earlier this week.

ALT GOV: The HHS “resistance” on social media

After a sequence of events that unfolded publicly on NCI’s Instagram feed May 28, RIFed and “retired” members of the NCI communications team took to the independent social media platform BlueSky, creating an alternative and anonymous social media presence.

June 06, 2025

Vol.51 No.22

By Claire Marie Porter

Clinical Roundup

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.

June 06, 2025

Vol.51 No.22

Clinical Roundup

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.

June 06, 2025

Vol.51 No.22

Grant-funded, investigator-initiated trials fail to bounce back from COVID as 50% of research staff left for higher-paying jobs

YOU MAY BE INTERESTED IN

George Sigounas named the first-ever chief science advisor at NCI

Success rates for RPGs at NCI would plummet from 13.4% to 8.3% if Trump’s FY2026 budget is enacted

FDA booth stood empty at 2025 ASCO annual meeting

ALT GOV: The HHS “resistance” on social media

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

Renew today!

Subscriber content

Never miss an issue!

Login